Research Studies: Multiple System Atrophy

Currently Enrolling Studies

TEVA: A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients with Multiple System Atrophy

• To determine if an oral investigational drug can stabilize, limit or slow the worsening of MSA symptoms and to determine how safe and well tolerated this drug is in adults with MSA.
• Participation in this research study will involve 7 visits to the research site and will last about 56 weeks.
• Male or female ≥30 years old with “clinically possible” or “clinically probable” MSA and able to ambulate at least 10 meters without the assistance of another person.

CYPRESS: A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy 

• To evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic Neurogenic orthostatic hypotension (dizziness, feeling light-headed, feeling faint, feeling like blacking out)  compared with placebo
•  This study is currently recruiting participants over the age of 30 with MSA

RT-QuIC: Premortem detection of misfolded proteins in biopsy skin samples and saliva in parkinsonism

• The purpose of this study is to analyze the effectiveness of a procedure called a skin punch biopsy to lead to an earlier diagnosis. Skin biopsy could be a useful way to diagnose and measure the severity of these conditions.

• Participation in this study would involve one visit lasting about 3 hours for a physical exam, questionnaires, a memory test, a punch skin biopsy, and blood draw.

Ongoing Studies Currently Closed to Enrollment

A Randomized Double-Blind, Placebo-Controlled Study of ATH434-201 to determine efficacy, safety and tolerability in patients with MSA (2)

• To assess the efficacy of the study drug (ATH434) in patients with MSA
• To assess whether the study drug (ATH434) is save and tolerable in patients with MSA
• Currently enrolling adults aged 30 to 75 with a confirmed diagnosis of MSA